Collaborative development financing could offer a more objective validation than a standard licensing deals because selection is based on the intrinsic value of the compounds, rather than strategic considerations that often sway a big pharma.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ransom, J. A reprise for collaborative financing in biotech. Nat Biotechnol 24, 873–874 (2006). https://doi.org/10.1038/nbt0806-873
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-873
- Springer Nature America, Inc.
This article is cited by
-
A better prescription for drug-development financing
Nature Biotechnology (2007)